Solid tumors occur when cells in an organ or tissue (for example in the lung or liver) start growing out of control (cancer) and form a lump or mass of cells. These solid cancers may grow very far in the general area where they started (called locally advanced) or ma...
We've found 35 total result s for "Solid Tumor".
The purpose of this first-in-human study is to identify a recommend dose(s) for subsequent larger studies (recommended dose(s) for expansion, RDE), examining increasing doses of M0324, primarily looking at safety, but also preliminary signs of efficacy, pharmacokinet...
Age: 18 years - 66+
Gender: All
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-deleted cancer cells while spar...
Age: 18 years - 66+
Gender: All
This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) ...
- Ovarian Neoplasms
- Endometrial Neoplasms
- Cholangiocarcinoma
- Central Nervous System Neoplasms
- Breast Neoplasms
- Fallopian Tube Neoplasms
- Carcinosarcoma
Age: 18 years - 66+
Gender: All
This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors
Age: 18 years - 66+
Gender: All
The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
- Neoplasm Metastasis
- Neoplasms
- Stomach Neoplasms
- Adenocarcinoma Of Esophagus
- Esophageal Squamous Cell Carcinoma
- Colorectal Neoplasms
Age: 18 years - 66+
Gender: All
BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-o...
- Neoplasm Metastasis
- Urinary Bladder Neoplasms
- Triple Negative Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Esophageal Neoplasms
- Pancreatic Neoplasms
- Ovarian Neoplasms
- Uterine Cervical Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Prostatic Neoplasms
- Urologic Neoplasms
- Ureteral Neoplasms
Age: 18 years - 66+
Gender: All
The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocel...
- Recurrence
- Endometrial Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Colorectal Neoplasms
- Carcinoma, Hepatocellular
- Adenocarcinoma Of Esophagus
- Carcinoma, Transitional Cell
- Ovarian Neoplasms
- Uterine Cervical Neoplasms
- Biliary Tract Neoplasms
- Melanoma
- Carcinoma, Neuroendocrine
Age: 18 years - 66+
Gender: All
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
- Ovarian Neoplasms
- Endometrial Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Testicular Germ Cell Tumor
- Testicular Neoplasms
Age: 15 years - 66+
Gender: All
This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recomm...
ASP1002 is being studied in people with tumors that have spread to nearby tissue (locally advanced) that cannot be removed by surgery (unresectable) or tumors that have spread to other parts of the body (metastatic). Claudin 4 protein, or CLDN4, is a protein found on ...
Age: 18 years - 66+
Gender: All
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer. Vepugratinib may be used to treat cancer of the cells that line the urinary syst...
- Urinary Bladder Neoplasms
- Neoplasm Metastasis
- Ureteral Neoplasms
- Urologic Neoplasms
- Non-Muscle Invasive Bladder Neoplasms
Age: 18 years - 66+
Gender: All
DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various t...
Age: 18 years - 66+
Gender: All
A Study of Emi-Le in Participants with Solid Tumors
- Triple Negative Breast Neoplasms
- Breast Neoplasms
- Endometrial Neoplasms
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Carcinoma, Adenoid Cystic
Age: 18 years - 66+
Gender: All
RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate...
Age: 18 years - 66+
Gender: All
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors
Age: 18 years - 66+
Gender: All
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demon...
- Urinary Bladder Neoplasms
- Ureteral Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Melanoma
- Esophageal Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Carcinoma, Ovarian Epithelial
- Fallopian Tube Neoplasms
- Endometrial Neoplasms
- Carcinoma, Renal Cell
- Rectal Neoplasms
- Colonic Neoplasms
Age: 18 years - 66+
Gender: All
This is a Phase 1 dose-escalation and cohort expansion study that will evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of LUNA18 when administered as a single agent or in combination with other anti-cancer drugs in patients...
Age: 18 years - 66+
Gender: All